

Technology



Wishing for a turnaround

Expect sequential improvement in a seasonally strong quarter

- We expect the revenues of IT services companies to recover following a tepid 4QFY24 for the industry, as the ramp-up of large cost-takeout deals could drive growth for large-caps in a seasonally strong quarter. The brutal winter of discretionary spend cuts in the industry is likely over, but there is little evidence of a recovery in the flow business. Hence, we are on track for one of the weakest first quarters for at least 10 years. The situation, though slightly better, is eerily similar to what we witnessed in 1HFY24. We would be looking for signs of recovery in discretionary spending in the form of deal activities, which have been heavily skewed towards cost-takeout projects. However, any disappointment in 1QFY25 could again put pressure on 2Q. While we expect ~5-7% YoY revenue growth in constant currency (cc) terms for HCL and TCS (lower for INFY largely due to a poor exit to FY24) for FY25, this is contingent on a recovery in the flow business and clients' willingness to resume discretionary spending. We believe mid-tier companies could continue to perform well, especially those with strong offerings in "pre-GenAI" spending, such as data engineering. We expect aggregate revenue/EBIT/PAT to grow by 3.2/5.2/6.1% respectively (all in INR terms) yoy for our coverage universe.
- Verticals such as BFS and Communications have been under pressure for the past 5-6 quarters; and while spending patterns remain largely unchanged, deal wins over the past couple of quarters should start accelerating in this quarter. This should offer some respite to growth rates for these verticals, especially for Infosys as the base becomes more favorable. Hi-tech, following a brief recovery, might face challenges, as spending on software moderates.
- The cross-currency impact for the quarter is expected to be minimal, as shown in Exhibit 5. On an average, we expect 10-20 cross-currency headwinds for our coverage on a sequential basis.
- Guidance: We expect no changes in guidance/commentary from companies on FY25 revenue growth. The focus of the commentaries is likely to remain on demand pick-up in 2HFY25, indicating a more normalized FY26 spending environment.
- We expect revenue growth of Tier-I companies to be in the range of -0.5% to +2.0% QoQ in CC. Revenue of Tier-II players is expected to grow by -1.5% to +5.0% QoQ in CC terms.
- Margins for the sector are likely to remain largely range-bound. The benefits from deferring wage hikes and benign currency movements could be offset by the ongoing challenge of recovering lost volumes. The first quarter is also anticipated to be affected by visa costs, leading to a slightly negative bias for the quarter. We believe FY25 will be a year of restrained wage hikes across the industry. Moreover, given the gradual nature of demand recovery, companies can adopt a more cautious approach towards their hiring strategies. This should lead to better margin defense for the sector.
- We prefer HCLT for its favorable business mix and reiterate the stock as our top pick among large-tier players. For mid-tier names, we continue to like Cyient despite the short-term headwinds, as its portfolio of aerospace, defense, and sustainability is set for decent growth over the medium term. Additionally, we prefer LTTS due to its well-diversified portfolio and market leadership.

Growth expectations across our coverage

- We expect Infosys and TCS to report relatively strong 2.0% and 1.6% QoQ CC revenue growth, respectively, whereas HCLT's 2% decline is already baked in (as guided last quarter). TechM and Wipro's revenue could be flat QoQ. LTIM is likely to report a relatively healthy 2% growth as well.
- Among mid-tier names, we expect Persistent to lead the pack with 5% QoQ revenue growth, largely driven by deal ramp-ups in the healthcare vertical. Coforge is likely to have a slightly slow quarter (around 1.5% QoQ growth), whereas Mphasis will grow about 1% QoQ.
- We expect Cyient to report a soft quarter as well, putting its FY25 guidance at risk. We model minimal cross-currency impact for the quarter for almost all companies (10-20bp adverse impact).

Margins a mixed bag

- We expect TCS' EBIT margin to contract by about 150bp QoQ, largely due to wage hikes. For HCL, the margin contraction should be steeper due to seasonality in its software business. For Infosys, we expect margin to improve slightly by 30bp as gains from its cost-benefit programs are offset by visa and other seasonal costs (with no wage hikes). TechM's margins are expected to remain muted, whereas Wipro should fare better.
- Among mid-caps, we expect most companies to report a sequential margin contraction. Coforge's margin should be down by ~80bp despite deferred wage hikes to 2QFY25. The large deal ramp-ups for Persistent would put its margin under pressure. Mphasis' margin would be range-bound, whereas LTTS should post a sequential margin contraction of ~50bp owing to low seasonal volumes.

Near-term demand unchanged; HCLT remains our top pick

- The near-term macro uncertainties and no meaningful sign of recovery in discretionary IT spending are key concerns for large-cap names; however, we expect mid-tier players to continue their outperformance.
- Among Tier-I players, HCLT is one of the key beneficiaries of having a defensive business mix, which should support its growth in the current environment.
- Among Tier-II players, our preference lies with CYL, which is poised for robust performance. This will be supported by the revival in the aerospace vertical, the moderating challenges in sectors such as railways and communications, and a strong portfolio in its sustainability business.

Exhibit 1: Expect Tier-I companies' revenue (USD) growth to recover after a subdued Q4FY24


		R	evenue (USD i	m)		Revenue (INR b)						
Company	1QFY25	4QFY24	QoQ (%)	1QFY24	YoY (%)	1QFY25	4QFY24	QoQ (%)	1QFY24	YoY (%)		
TCS	7,459	7,363	1.3	7,226	3.2	622	612	1.6	594	4.8		
INFO	4,651	4,564	1.9	4,617	0.7	388	379	2.3	379	2.3		
HCLT	3,365	3,430	-1.9	3,200	5.2	279	285	-2.0	263	6.2		
WPRO	2,646	2,657	-0.4	2,779	-4.8	222	222	-0.2	228	-2.9		
TECHM	1,554	1,548	0.4	1,601	-2.9	130	129	0.7	132	-1.5		
LTIM	1,077	1,069	0.7	1,059	1.7	90	89	1.0	87	3.2		
Tier I aggregate	20,752	20,632	0.6	20,481	1.3	1,731	1,716	0.8	1,683	2.8		
			EBIT margin (%	6)		Adjusted PAT (INR b)						
Company	1QFY25	4QFY24	QoQ (bps)	1QFY24	YoY (bps)	1QFY25	4QFY24	QoQ (%)	1QFY24	YoY (%)		
TCS	24.5	26.0	-150.0	23.2	130.0	121.4	125.0	-2.9	111.2	9.2		
INFO	20.4	20.1	30.0	20.8	-40.0	63.1	60.8	3.8	59.5	6.1		
HCLT	16.8	17.6	-80.0	17.0	-10.0	37.7	40.0	-5.7	35.3	6.6		
WPRO	15.8	15.9	-10.0	15.1	70.0	28.9	28.6	1.1	28.9	0.1		
TECHM	7.7	7.4	30.0	8.8	-110.0	8.1	9.7	-15.8	9.6	-15.1		
LTIM	15.6	14.7	90.0	16.7	-110.0	11.6	11.0	5.4	11.5	0.7		
Tier I aggregate	19.5	20.0	-50.0	19.1	40.0	271	275	-1.5	256	5.8		

Exhibit 2: Expect Tier-II players' revenue (USD) growth to be robust with a few exceptions

		Re	venue (USD m	1)		Revenue (INR b)						
Company	1QFY25	4QFY24	QoQ (%)	1QFY24	YoY (%)	1QFY25	4QFY24	QoQ (%)	1QFY24	YoY (%)		
LTTS	303	305	-0.6	280	8.4	25.3	25.4	-0.3	23.0	10.0		
MPHL	416	411	1.2	398	4.5	34.7	34.2	1.6	32.7	6.0		
COFORGE	291	287	1.5	272	7.1	24.3	23.6	3.0	22.2	9.4		
PSYS	327	311	5.2	283	15.6	27.2	25.9	5.2	23.2	17.4		
ZENT	151	148	2.3	149	1.5	12.6	12.3	2.8	12.3	3.0		
CYL	177	179	-1.4	177	-0.2	14.7	14.9	-1.0	14.5	1.4		
Tier II aggregate	1,666	1,641	1.5	1,559	6.8	138.9	136.2	2.0	128.0	8.5		
		E	BIT margin (%))		Adjusted PAT (INR b)						
Company	1QFY25	4QFY24	QoQ (bps)	1QFY24	YoY (bps)	1QFY25	4QFY24	QoQ (%)	1QFY24	YoY (%)		
LTTS	16.4	16.9	-50.0	17.2	-80.0	3.4	3.4	-0.7	3.1	8.8		
MPHL	15.3	14.9	40.0	15.3	-	4.3	3.9	8.1	4.0	7.4		
COFORGE	13.3	14.1	-80.0	11.5	170.0	2.4	2.2	4.7	1.8	29.3		
PSYS	14.0	14.5	-50.0	14.9	-90.0	3.2	3.2	2.0	2.8	15.9		
ZENT	13.9	14.6	-70.0	15.3	-140.0	1.5	1.7	-16.1	1.6	-6.9		
CYL	16.4	16.0	40.0	16.1	30.0	1.9	1.9	1.4	1.8	8.6		
Tier II aggregate	14.9	15.1	-20.0	15.0	-10.0	16.6	16.4	1.3	15.0	10.6		


Source: Company, MOFSL

Exhibit 3: Revenue growth to see a slight uptick for Tier-I companies after a difficult 4QFY24



Source: MOFSL, Company

Exhibit 4: Tier-I should perform better on the margin front



Source: MOSL, Company

Exhibit 5: Cross-currency to have an adverse impact on 1Q USD revenue growth

	CC USD growth QoQ (%)	USD growth QoQ (%)	Cross-currency impact (bp)
TCS	1.6	1.3	-30
INFO	2.0	1.9	-10
HCLT	-1.8	-1.9	-10
WPRO	-0.5	-0.4	10
TECHM	0.8	0.4	-40
LTIM	0.7	0.7	-
LTTS	-0.5	-0.6	-
MPHL	1.2	1.2	-
COFORGE	1.4	1.5	10
PSYS	5.0	5.2	10
ZENT	1.9	1.9	-
CYL (DET)	-1.5	-1.4	10

Source: Company, MOFSL

Exhibit 6: Relative performance - three-months (%)





Exhibit 7: Relative performance – one-year (%)



Source: Bloomberg, MOFSL

Exhibit 8: Expected quarterly performance summary

	СМР		S	ales (INR b)		EBIT (INR b)	Adjuste	d net profi	t (INR b)
Companies	(INR)	Rating	June'24E	Variance YoY (%)	Variance QoQ (%)	Jun'24E	Variance YoY (%)	Variance QoQ (%)	Jun'24E	Variance YoY (%)	Variance QoQ (%)
TCS	3,972	Buy	622.2	4.8	1.6	152.4	10.8	-4.2	121.4	9.2	-2.9
INFO	1,592	Buy	388.0	2.3	2.3	79.2	0.4	4.0	63.1	6.1	3.8
HCLT	1,472	Buy	279.3	6.2	-2.0	47.0	5.3	-6.4	37.7	6.6	-5.7
WPRO	529	Neutral	221.6	-2.9	-0.2	35.1	1.7	-0.8	28.9	0.1	1.1
TECHM	1,473	Neutral	129.6	-1.5	0.7	10.0	-13.5	5.5	8.1	-15.1	-15.8
LTIM	5,454	Neutral	89.8	3.2	1.0	14.0	-3.4	7.1	11.6	0.7	5.4
MPHL	2,510	Neutral	34.7	6.0	1.6	5.3	6.1	4.4	4.3	7.4	8.1
LTTS	5,021	Buy	25.3	10.0	-0.3	4.2	5.0	-3.1	3.4	8.8	-0.7
PSYS	4,541	Neutral	27.2	17.4	5.2	3.8	10.0	1.9	3.2	15.9	2.0
COFORGE	5,513	Neutral	24.3	9.4	3.0	3.2	25.9	-2.8	2.4	29.3	4.7
CYL	1,835	Buy	14.7	1.4	-1.0	2.4	3.5	1.4	1.9	8.6	1.4
ZENT	754	Neutral	12.6	3.0	2.8	1.8	-6.5	-2.0	1.5	-6.9	-16.1
Sector aggregate (INR b)			1,872	3.3	0.9	358	5.1	-1.6	287	6.1	-1.4

Source: Company, MOFSL

Exhibit 9: Comparative valuations

Company CMP (INR)	_	M-cap (INR b)	Target Price	Upside/ Downside		EPS (INR)		EPS CAGR (%)	Dividend yield (%)		P/E (x)	
	(IINK)	(IINK D)	Price	(%)	FY24	FY25E	FY26E	FY24-26E	FY24	FY24	FY25E	FY26E
TCS	3,972	14,484	4,660	17	126.3	143.1	155.2	10.9	3.2	31.5	27.8	25.6
INFO	1,592	6,610	1,845	16	58.4	63.5	73.8	12.4	2.9	27.2	25.1	21.6
HCLT	1,472	3,965	1,710	16	57.9	62.5	68.4	8.7	3.3	25.4	23.5	21.5
WPRO	529	2,733	490	-7	20.4	22.2	24.5	9.6	4.6	25.9	23.8	21.6
TECHM	1,473	1,208	1,355	-8	41.1	43.9	64.3	25.1	2.7	35.8	33.6	22.9
LTIM	5,454	1,440	5,805	6	154.8	167.7	193.4	11.8	1.2	35.2	32.5	28.2
MPHL	2,510	469	2,335	-7	81.8	93.7	101.1	11.2	2.0	30.7	26.8	24.8
LTTS	5,021	533	5,965	19	123.0	135.3	156.9	12.9	0.9	40.8	37.1	32.0
PSYS	4,541	651	4,560	0.4	75.1	93.4	113.9	23.2	0.8	60.5	48.6	39.9
COFORGE	5,513	341	6,100	11	133.0	169.2	203.3	23.6	1.3	41.4	32.6	27.1
CYL	1,835	203	2,160	18	62.1	81.2	99.3	26.4	1.6	29.5	22.6	18.5
ZENT	754	170	750	-1	29	27	33	4.6	0.9	25.9	28.4	23.2

Source: Company, MOFSL

The tables below provide a snapshot of actual and estimated numbers for IT companies under the MOFSL coverage universe. Highlighted columns indicate the quarter/financial year under review.

Coforge **Neutral**

CMP INR5513 | TP: INR6100 (11%)

EPS CHANGE (%): FY25 | 26: -11.1 | -9.7

- Revenue growth is likely to be ~1.5% QoQ; expect acceleration Key monitorables: further clarity on integration of Cigniti in growth from 2Q onwards as deals ramp-up
 - as well as demand environment in BFSI
- EBIT margin is expected to contract ~80bp QoQ due to visa costs as well as some decline in utilization
- We expect Coforge to report ~11% CC growth in FY25.

Quarterly performance (Ind-AS)

Y/E March		FY2	4			FY25	Ε		FY24	FY25E
(Consolidated)	1Q	2Q	3Q	4Q	1QE	2QE	3QE	4QE		
Rev. (USD m)	272	278	282	287	291	305	316	330	1,119	1,242
QoQ (%)	2.8	2.3	1.4	1.7	1.5	4.7	3.6	4.5	11.7	11.1
Revenue (INR m)	22,210	22,762	23,233	23,585	24,289	25,445	26,367	27,551	91,790	1,03,652
YoY (%)	21.4	16.2	13.0	8.7	9.4	11.8	13.5	16.8	14.5	12.9
GPM (%)	30.7	32.5	33.1	34.1	32.5	32.0	33.5	34.0	32.6	33.0
SGA (%)	14.7	14.9	15.1	15.5	15.0	15.0	15.0	15.0	15.1	15.0
EBITDA (INR m)	3,316	3,473	4,012	4,163	4,024	4,088	4,632	4,978	14,964	17,723
EBITDA margin (%)	14.9	15.3	17.3	17.7	16.6	16.1	17.6	18.1	16.3	17.1
EBIT (INR m)	2,559	2,701	3,201	3,317	3,223	3,249	3,762	4,069	11,778	14,302
EBIT margin (%)	11.5	11.9	13.8	14.1	13.3	12.8	14.3	14.8	12.8	13.8
Other income	-152	-295	-257	-452	-243	-254	-264	-276	-1,156	-1,037
ETR (%)	20.1	21.9	17.5	19.7	18.8	18.8	18.8	18.8	19.7	18.8
Minority Interest	-104.0	-69.0	-48.0	-55.0	-69.6	-69.6	-69.6	-69.6	-276.0	-278.5
Adj. PAT	1,818	1,809	2,380	2,246	2,351	2,363	2,772	3,012	8,253	10,498
QoQ (%)	-21.9	-0.5	31.6	-5.6	4.7	0.5	17.3	8.6		
YoY (%)	21.2	-10.3	4.3	-3.5	29.3	30.6	16.5	34.1	1.6	27.2
Adj. EPS (INR)	29.2	29.0	38.1	36.2	37.9	38.1	44.7	48.5	133.0	169.2

Cyient Buv

CMP INR1835 | TP: INR2160 (+18%)

EPS CHANGE (%): FY25 | 26: -5.6 | -11.4

- Expect 1.5% QoQ CC decline for DET in 1QFY25 due to planned ramp downs in some projects and supply crunch in its key aerospace vertical
- DET margin is likely to improve ~40bp QoQ, and the company should deliver on its guidance band.
- Sustainability is performing well but planned ramp downs could lead to a decline in 1Q in the vertical

We expect risks to its FY25 guidance in light of the shortterm headwinds in its key verticals.

Quarterly performance (Consol)

Y/E March		FY24	1			FY25	E		FY24	FY25E
	1Q	2Q	3Q	4Q	1QE	2QE	3QE	4QE		
Revenue (USD m)	205	214	219	224	213	224	233	250	862	920
QoQ (%)	-3.6	4.4	2.1	2.4	-4.7	5.0	3.9	7.4	15.5	6.7
Revenue (INR m)	16,865	17,785	18,215	18,607	17,801	18,696	19,421	20,859	71,472	76,777
YoY (%)	34.9	27.4	12.6	6.2	5.6	5.1	6.6	12.1	18.8	7.4
GPM (%)	36.6	35.7	35.4	35.2	36.2	37.6	37.9	38.0	35.7	37.5
SGA (%)	17.9	17.4	17.5	17.2	18.2	18.4	18.4	18.4	17.5	18.4
EBITDA	3,156	3,258	3,261	3,353	3,204	3,590	3,787	4,088	13,028	14,669
EBITDA margin (%)	18.7	18.3	17.9	18.0	18.0	19.2	19.5	19.6	18.2	19.1
EBIT	2,480	2,600	2,600	2,682	2,492	2,842	3,010	3,254	10,362	11,598
EBIT margin (%)	14.7	14.6	14.3	14.4	14.0	15.2	15.5	15.6	14.5	15.1
Other income	-176	-134	-100	-89	36	37	39	42	-499	154
ETR (%)	22.9	23.6	23.3	24.0	24.1	24.1	24.1	24.1	23.5	24.1
Adj. PAT	1,767	1,831	1,858	1,893	1,920	2,186	2,315	2,503	7,349	8,924
QoQ (%)	0.3	3.6	1.5	1.9	1.4	13.9	5.9	8.1		
YoY (%)	52.2	50.3	14.1	7.4	8.6	19.4	24.6	32.2	27.4	21.4
EPS (INR)	16.0	16.6	16.9	17.2	17.5	19.9	21.1	22.8	66.9	81.2

HCL Technologies

Buv

CMP INR1472 | TP: INR1710 (+16%)

EPS CHANGE (%): FY25 | 26: -0.3 | -7.1

 We expect HCLT to report a revenue decline of ~2% QoQ in a seasonally weak quarter.

Margin to contract 80bp QoQ due to seasonal headwinds

Revenue decline would be largely due to annual productivity pass-backs to clients and a few planned ramp downs in its IT services business.

We expect the company to retain its FY25 revenue growth guidance of 3-5%.

Quarterly performance

Y/E March		FY24				FY2	5E		FY24	FY25E
	1Q	2Q	3Q	4Q	1QE	2Q	3Q	4QE		
Revenue (USD m)	3,200	3,225	3,415	3,430	3,365	3,433	3,581	3,589	13,270	13,969
QoQ (%)	-1.1	0.8	5.9	0.4	-1.9	2.0	4.3	0.2	5.4	5.3
Revenue (INR b)	263	267	284	285	279	285	297	298	1,099	1,159
YoY (%)	12.1	8.0	6.5	7.1	6.2	6.8	4.5	4.5	8.3	5.5
GPM (%)	35.6	36.2	36.7	35.0	34.6	35.1	36.3	37.3	35.9	35.9
SGA (%)	13.6	12.4	11.5	12.0	12.3	12.4	12.0	12.0	12.4	12.2
EBITDA	55	59	67	61	47	49	57	60	242	258
EBITDA margin (%)	20.8	22.3	23.5	21.4	16.8	17.3	19.1	20.1	22.0	22.3
EBIT	45	49	56	50	47	49	57	60	200	213
EBIT margin (%)	17.0	18.5	19.7	17.6	16.8	17.3	19.1	20.1	18.2	18.4
Other income	2	2	3	3	3	3	3	3	9	11
ETR (%)	24.8	25.3	25.9	24.2	24.2	24.2	24.2	24.2	25.1	24.2
Adjusted PAT	35	38	44	40	38	39	45	48	157	170
QoQ (%)	-11.2	8.4	13.5	-8.4	-5.7	5.1	14.4	5.2		
YoY (%)	7.6	9.8	6.2	0.1	6.3	3.0	3.8	19.2	5.7	8.1
EPS	13.0	14.1	16.0	14.7	13.8	14.5	16.6	17.5	57.9	62.5

Infosys

Buy

CMP INR1592 | TP: INR1845 (+16%)

EPS CHANGE (%): FY25 | 25: -0.5 | -0.3

- Revenue growth is expected to rebound to 2.0% QoQ CC, on account of ramp-up of large deals won in FY24.
- We expect the deal TCV to be robust in 1Q; however, deals should be skewed towards the cost-takeout initiatives
- Operating margin is expected to inch up by 30bp owing to growth and absence of wage hikes. We expect the company's operating margin to be at 20.4%.
- Expect Infosys to maintain its growth guidance of 1-3% CC for FY25.

Quarterly performance (IFRS)

Y/E March		FY24	1			FY25	iΕ		FY24	FY25E
	1Q	2Q	3Q	4Q	1QE	2QE	3QE	4QE		
Revenue (USD m)	4,617	4,718	4,663	4,564	4,651	4,768	4,815	4,863	18,562	19,098
QoQ (%)	1.4	2.2	-1.2	-2.1	1.9	2.5	1.0	1.0	1.9	2.9
Revenue (INR m)	379	390	388	379	388	398	402	406	1,537	1,587
YoY (%)	10.0	6.7	1.3	1.3	2.3	2.0	3.5	7.0	4.7	3.2
GPM (%)	30.5	30.7	29.8	29.5	29.8	30.7	30.7	29.7	30.1	30.2
SGA (%)	9.6	9.5	9.3	9.4	9.4	9.4	9.4	9.4	9.4	9.4
EBITDA	98	103	100	96	79	85	86	82	397	332
EBITDA margin (%)	26.0	26.4	25.7	25.2	20.4	21.3	21.3	20.3	25.8	20.9
EBIT	79	83	80	76	79	85	86	82	317	331
EBIT margin (%)	20.8	21.2	20.5	20.1	20.4	21.3	21.3	20.3	20.7	20.8
Other income	5	5	7	7	7	7	7	7	23	27
ETR (%)	28.9	29.1	29.1	26.8	26.5	26.5	26.5	26.5	28.5	26.5
PAT	59	62	61	61	63	67	68	66	243	263
QoQ (%)	-3.0	4.5	-1.7	-0.5	3.9	6.7	1.0	-3.4		
YoY (%)	10.9	3.2	-7.3	-0.9	6.1	8.3	11.3	8.1	1.0	8.0
EPS (INR)	14.4	15.0	14.7	14.7	15.2	16.2	16.4	15.8	58.4	63.5

LTIMindtree Neutral

CMP INR5454 | TP: INR5805(+6%)

EPS CHANGE (%): FY25 | 26: -0.4 | -3.7

- LTIM should report 0.7% CC growth in 1Q, dragged by weak demand environment and soft discretionary spending.
- Margin is likely to see a sequential pickup of 90bp QoQ due to reversion of a one-off impact and better operating leverage.
- Manufacturing is expected to perform along similar lines, whereas BFSI should see tailwinds from the low-base effect.
- In 1QFY25, demand commentary will be closely monitored coupled with the BFSI vertical's performance.

Quarterly performance

Y/E March		FY24	ļ			FY25	E		FY24	FY25E
	1Q	2Q	3Q	4Q	1QE	2QE	3QE	4QE		
Revenue (USD m)	1,059	1,076	1,084	1,069	1,077	1,104	1,141	1,175	4,287	4,497
QoQ (%)	0.1	1.6	0.8	-1.3	0.7	2.5	3.4	3.0	4.4	4.9
Revenue (INR m)	87,021	89,054	90,166	88,929	89,827	92,084	95,217	98,038	3,55,170	3,75,166
YoY (%)	13.8	8.2	4.6	2.3	3.2	3.4	5.6	10.2	7.0	5.6
GPM (%)	31.6	31.4	29.9	29.8	30.7	29.7	31.5	31.5	30.7	30.9
SGA (%)	12.8	13.1	12.3	12.5	13.0	12.6	13.0	12.5	12.7	12.8
EBITDA	16,355	16,313	15,849	15,357	15,899	15,746	17,615	18,627	63,874	67,888
EBITDA margin (%)	18.8	18.3	17.6	17.3	17.7	17.1	18.5	19.0	18.0	18.1
EBIT	14,508	14,231	13,859	13,087	14,013	13,813	15,616	16,568	55,685	60,010
EBIT margin (%)	16.7	16.0	15.4	14.7	15.6	15.0	16.4	16.9	15.7	16.0
Other income	856	962	1,588	1,396	1,258	1,289	1,333	1,471	4,802	5,350
ETR (%)	25.0	23.5	24.3	24.0	24.0	24.0	24.0	24.0	24.2	24.0
Adj. PAT	11,523	11,623	11,693	11,007	11,606	11,478	12,882	13,710	45,846	49,676
QoQ (%)	3.4	0.9	0.6	-5.9	5.4	-1.1	12.2	6.4		
YoY (%)	4.1	-2.2	8.2	-1.2	0.7	-1.2	10.2	24.6	2.1	8.4
EPS (INR)	38.9	39.2	39.4	37.1	39.2	38.7	43.5	46.3	154.8	167.7

LTTS Buy

CMP INR5021 | TP: INR5965 (+19%)

EPS CHANGE (%): FY25|26: -10.5|-11.7

- We expect revenue to be flat, with a slight negative bias in ■ We expect the deal momentum to continue in 1Q 1Q; seasonality in the SWC business to be offset by the
- recent large deal ramp ups
- EBIT margin to contract ~40bp QoQ due to large deal ramp■ We expect the company to retain its FY25 USD CC revenue growth guidance of 8-10%, aided by strong deal pipeline

Quarterly performance

Y/E March		FY24	1			FY25	E		FY24	FY25E
	1Q	2Q	3Q	4Q	1QE	2QE	3QE	4QE		
Revenue (USD m)	280	288	291	305	303	312	319	334	1,164	1,269
QoQ (%)	9.8	2.9	0.9	5.0	-0.6	2.9	2.2	4.4	17.6	9.0
Revenue (INR m)	23,014	23,865	24,218	25,375	25,308	26,059	26,644	27,828	96,472	1,05,839
YoY (%)	22.8	19.6	18.2	21.1	10.0	9.2	10.0	9.7	20.4	9.7
GPM (%)	30.0	28.0	29.2	28.9	29.0	28.8	29.8	30.0	29.0	29.4
SGA (%)	10.4	8.1	9.1	9.1	9.8	9.7	10.2	10.2	9.1	10.0
EBITDA	4,528	4,756	4,877	5,028	4,859	4,977	5,222	5,510	19,189	20,569
EBITDA margin (%)	19.7	19.9	20.1	19.8	19.2	19.1	19.6	19.8	19.9	19.4
EBIT	3,954	4,075	4,162	4,282	4,151	4,248	4,476	4,731	16,473	17,605
EBIT margin (%)	17.2	17.1	17.2	16.9	16.4	16.3	16.8	17.0	17.1	16.6
Other income	357	286	493	428	456	469	480	501	1,564	1,905
ETR (%)	27.6	27.6	27.6	27.5	26.5	26.5	26.5	26.5	27.6	26.5
PAT	3,111	3,154	3,362	3,409	3,385	3,467	3,642	3,845	13,036	14,340
QoQ (%)	0.5	1.4	6.6	1.4	-0.7	2.4	5.1	5.6		
YoY (%)	13.5	11.7	10.7	10.1	8.8	9.9	8.3	12.8	11.4	10.0
EPS (INR)	29.4	29.8	31.7	32.2	31.9	32.7	34.4	36.3	123.0	135.3

Mphasis Neutral

CMP INR2510 | TP: INR2335 (-7%)

EPS CHANGE (%): FY25 | 26: -0.8 | -10.3

- We expect a revenue growth of 1.2% QoQ CC, led by growth in BFSI and TMT verticals.
- The mortgage business should normalize in 1Q and is unlikely to see any further deterioration; however, we do not see any significant growth in this business until macros improve
- We expect margin to improve 40bp QoQ on continued cost optimization improvements.
- Commentary towards demand environment and pricing, volume recovery for its mortgage business, and deal TCVs need to be closely monitored.

Quarterly performance

Y/E March		FY24	4			FY25	E		FY24	FY25E
	1Q	2Q	3Q	4Q	1QE	2QE	3QE	4QE		
Revenue (USD m)	398	398	402	411	416	426	436	448	1,609	1726
QoQ (%)	-3.4	0.1	1.0	2.1	1.2	2.6	2.3	2.6	-6.3	7.3
Revenue (INR m)	32,520	32,765	33,380	34,120	34,653	35,544	36,374	37,310	1,32,785	143880
YoY (%)	-4.7	-6.9	-4.8	1.5	6.6	8.5	9.0	9.3	-3.8	8.4
GPM (%)	29.1	28.9	31.3	31.2	30.3	30.0	29.6	29.3	30.1	29.8
SGA (%)	11.1	10.7	13.3	12.5	12.5	12.2	12.0	11.6	11.9	12.1
EBITDA	5,869	5,956	6,007	6,388	6,168	6,327	6,402	6,604	24,220	25501
EBITDA margin (%)	18.0	18.2	18.0	18.7	17.8	17.8	17.6	17.7	18.2	17.7
EBIT	4,995	5,067	4,972	5,080	5,302	5,545	5,565	5,820	20,114	22232
EBIT margin (%)	15.4	15.5	14.9	14.9	15.3	15.6	15.3	15.6	15.1	15.5
Other income	263	150	14	143	347	355	364	373	570	1439
ETR (%)	24.7	24.9	25.1	24.7	24.7	24.7	24.7	24.7	24.8	24.7
PAT	3,961	3,920	3,736	3,932	4,252	4,442	4,463	4,663	15,549	17820
QoQ (%)	-2.3	-1.0	-4.7	5.2	8.1	4.5	0.5	4.5		
YoY (%)	-1.5	-6.3	-9.4	-3.0	7.4	13.3	19.5	18.6	-5.1	14.6
EPS (INR)	20.9	20.6	19.6	20.7	22.4	23.4	23.5	24.5	81.8	93.7

Persistent Systems

Neutral

CMP INR4541 | TP: INR4560 (0.4%)

EPS CHANGE (%): FY25 | 26: -1.7 | -3.0

- Expect revenue growth of ~5% QoQ CC, aided by continued momentum in Healthcare and ramp up of large deals in the vertical
- Margin is likely to contract 50bp QoQ and will be under pressure due to the initial ramp-up costs for large deals
- Expect healthy deal momentum to continue, with continued strength in healthcare followed by the BFS vertical
- Commentary on the recovery in hi-tech vertical is a key monitorable

Quarterly performance (IFRS)

Y/E March		FY2	1			FY25	E		FY24	FY25E
(Consolidated)	1Q	2Q	3Q	4Q	1QE	2QE	3QE	4QE		
Revenue (USD m)	282.9	291.7	300.6	310.9	326.9	337.0	348.0	359.3	1,186	1,371
QoQ (%)	3.0	3.1	3.0	3.4	5.2	3.1	3.3	3.3	14.5	15.6
Revenue (INR m)	23,212	24,117	24,982	25,905	27,243	28,081	28,997	29,944	98,216	1,14,266
QoQ (%)	3.0	3.9	3.6	3.7	5.2	3.1	3.3	3.3		
YoY (%)	23.6	17.7	15.2	14.9	17.4	16.4	16.1	15.6	17.6	16.3
GPM (%)	34.2	33.1	33.8	33.3	32.5	32.8	33.5	34.0	33.6	33.2
SGA (%)	16.0	16.3	16.1	15.7	15.4	15.3	15.3	15.3	16.0	15.3
EBITDA	4,229	4,052	4,418	4,544	4,658	4,914	5,278	5,600	17,243	20,450
EBITDA margin (%)	18.2	16.8	17.7	17.5	17.1	17.5	18.2	18.7	17.6	17.9
EBIT	3,466	3,308	3,631	3,744	3,814	4,044	4,379	4,671	14,149	16,908
EBIT margin (%)	14.9	13.7	14.5	14.5	14.0	14.4	15.1	15.6	14.4	14.8
Other income	90	250	262	210	218	225	232	240	813	914
ETR (%)	22.0	26.0	26.5	20.3	20.3	20.3	20.3	20.3	23.7	20.3
PAT	2,774	2,633	2,861	3,153	3,215	3,404	3,676	3,916	11,421	14,211
QoQ (%)	10.3	-5.1	8.7	10.2	2.0	5.9	8.0	6.5		
YoY (%)	31.1	19.7	6.9	25.4	15.9	29.3	28.5	24.2	20.1	24.4
EPS (INR)	15.0	17.3	18.8	20.7	21.1	22.4	24.2	25.7	71.9	93.4

TCS

CMP INR3972 | TP: INR4660 (+17%)

EPS CHANGE (%): FY25 | 26: -2.5 | -8.5

- Growth is expected to be 1.6% QoQ CC, led by deal scale up, including the BSNL deal, which is ramping up as per plan.
- The deal pipeline should remain healthy
- EBIT margin is expected to contract 150bp qoq owing to wage hikes in 1QFY25.
- Outlook on near-term demand & pricing environment, BFSI, and deal wins are key monitorables.

Quarterly performance (IFRS)

Y/E March		FY24	ļ			FY25	E	_	FY24	FY25E
	1Q	2Q	3Q	4Q	1QE	2QE	3QE	4QE		
IT Services Revenue (USD m)	7,226	7,210	7,281	7,363	7,459	7,656	7,820	8,037	29,080	29,313
QoQ (%)	0.4	-0.2	1.0	1.1	1.3	2.6	2.1	2.8	4.1	0.8
Overall Revenue (INR b)	594	597	606	612	622	639	652	670	2,409	2,437
QoQ (%)	0.4	0.5	1.5	1.1	1.6	2.6	2.1	2.8		
YoY (%)	12.6	7.9	4.0	3.5	4.8	7.0	7.7	9.5	6.8	1.2
GPM (%)	39.5	40.1	40.8	41.1	40.0	40.9	41.0	41.0	40.4	40.7
SGA (%)	16.4	15.8	15.8	15.1	15.5	15.5	15.5	15.5	15.7	15.5
EBITDA	150	157	164	172	152	162	166	171	643	646
EBITDA margin (%)	25.2	26.3	27.1	28.1	24.5	25.4	25.5	25.5	26.7	26.5
EBIT	138	145	152	159	152	162	166	171	594	652
EBIT margin (%)	23.2	24.3	25.0	26.0	24.5	25.4	25.5	25.5	24.7	25.2
Other income	12	8	7	9	11	11	12	12	37	36
PBT	150	153	159	168	163	173	178	183	632	697
ETR (%)	25.8	25.8	25.8	25.8	25.5	25.5	25.5	25.5	25.7	25.5
Adj. PAT	111	114	118	125	121	129	133	136	469	519
Exceptional items	0	0	-7	0	0	0	0	0	-7	0
Reported PAT	111	114	111	125	121	129	133	136	462	519
QoQ (%)	-2.8	2.3	-2.5	12.7	-2.9	6.2	2.9	2.8		
YoY (%)	16.8	8.7	2.0	9.3	9.2	13.3	19.6	9.1	9.3	12.3
EPS (INR)	30.3	31.0	30.3	34.4	33.4	35.5	36.6	37.6	126.3	143.1

Tech Mahindra Neutral

CMP INR1473 | TP: INR1355 (-8%)

EPS CHANGE (%): FY25 | 26: -13.7 | -17.3

- Revenue growth is expected to be muted at 0.4% QoQ CC; while communications vertical has bottomed out, recovery could take longer
- Margin is likely to improve slightly by 30bp QoQ, as the impact of cost-control efforts should start becoming visible. Weak growth is likely to keep margins under pressure
- Deal wins are likely to be muted due to macro uncertainty. We expect deal TCV to the tune of USD500m in 1Q
- The outlook on margin and growth in the CME and BFS verticals will be the key monitorables.

Quarterly performance

Y/E March		FY24	ļ			FY25	E		FY24	FY25E
	1Q	2Q	3Q	4Q	1QE	2QE	3QE	4QE		
Revenue (USD m)	1,601	1,555	1,573	1,548	1,554	1,592	1,616	1,657	6,277	6,419
QoQ (%)	-4.0	-2.8	1.1	-1.6	0.4	2.4	1.6	2.5	-5.0	2.3
Revenue (INR b)	132	129	131	129	130	133	135	138	520	536
YoY (%)	3.5	-2.0	-4.6	-6.2	-1.5	3.2	2.9	7.4	-2.4	3.0
GPM (%)	25.7	22.5	23.9	27.0	26.0	25.7	26.2	26.3	24.8	26.1
SGA (%)	13.5	11.5	13.6	16.1	15.0	14.0	13.5	13.0	13.7	13.9
EBITDA	16	14	14	14	14	16	17	18	58	65
EBITDA margin (%)	12.2	10.9	10.3	10.9	11.0	11.7	12.7	13.3	11.1	12.2
EBIT	12	9	9	9	10	11	13	14	40	48
EBIT margin (%)	8.8	7.3	7.0	7.4	7.7	8.4	9.4	10.0	7.6	8.9
Other income	1	2	0	3	1	1	1	1	5	3
ETR (%)	21.8	9.9	17.6	23.4	23.4	23.4	23.4	23.4	18.5	23.4
Adj. PAT	10	10	7	10	8	9	10	11	36	39
QoQ (%)	-28.2	2.3	-26.5	34.9	-15.7	11.1	12.9	8.7		
YoY (%)	-15.5	-25.3	-44.6	-27.1	-14.4	-7.1	42.8	15.0	-28.5	6.8
Extra-Ordinary Item	-2.6	-4.8	-2.1	-3.1	0.0	0.0	0.0	0.0	-12.6	0.0
Reported PAT	7	5	5	7	8	9	10	11	24	39
EPS (INR)	10.8	11.0	8.1	11.0	9.3	10.3	11.6	12.7	41.1	43.9

Wipro Neutral

CMP INR529 | TP: INR490 (-7%)

EPS CHANGE (%): FY25 | 26: -17.4 | -8.9

- We expect WPRO to report ~0.5% decline in 1Q due to the macro impact and continued softness in verticals.
- We expect continued softness in key verticals such as retail
 and communications led by cautious client spending
 behavior
- The IT services' margin is expected to be range bound, and could see a marginal dip
 - Commentary on recovery in the consulting business as well as strategic initiatives from the new management will be the key monitorables

Quarterly performance (IFRS)

Y/E March		FY24				FY25	E		FY24	FY25E
	1Q	2Q	3Q	4Q	1QE	2QE	3QE	4QE		
IT Services Revenue (USD m)	2,779	2,713	2,656	2,657	2,646	2,700	2,741	2,796	10,805	10,883
QoQ (%)	-2.1	-2.3	-2.1	0.0	-0.4	2.1	1.5	2.0	-3.8	0.7
Overall Revenue (INR b)	228	225	222	222	222	226	230	234	896	912
QoQ (%)	-1.5	-1.4	-1.4	0.0	-0.2	2.1	1.4	2.1		
YoY (%)	6.0	-0.1	-4.4	-4.2	-2.9	0.5	3.4	5.5	-0.9	1.7
GPM (%)	29.4	29.3	30.7	29.2	30.0	30.2	29.7	29.7	29.6	29.9
SGA (%)	14.2	14.6	16.0	13.2	14.1	14.1	14.1	14.1	14.5	14.1
EBITDA	42	42	42	44	35	36	36	36	170	216
EBITDA margin (%)	18.4	18.8	19.0	19.7	15.8	16.0	15.5	15.5	19.0	23.7
IT Services EBIT (%)	16.0	16.1	16.0	16.4	17.3	17.5	16.9	16.9	16.4	17.2
EBIT margin (%)	15.1	14.8	14.8	15.9	15.8	16.0	15.5	15.5	15.2	15.7
Other income	3	2	3	3	3	3	3	3	11	12
ETR (%)	24.0	24.0	24.0	26.0	24.0	24.0	24.0	24.0	24.5	24.0
PAT	29	26	27	28	29	30	29	30	110	117
QoQ (%)	-6.6	-7.8	1.8	5.2	1.4	3.2	-1.6	1.9		
YoY (%)	12.0	-0.5	-11.7	-7.8	0.1	12.0	8.3	4.9	-2.9	6.4
EPS (INR)	5.1	5.0	5.2	5.4	5.5	5.7	5.6	5.7	20.4	22.2

Zensar Technologies

Neutral

CMP INR754 | TP: INR750 (-1%)

EPS CHANGE (%): FY25 | 26: 7.7 | 14.2

- We expect revenue growth of 1.9% QoQ CC in 1QFY25
- We expect margin to moderate ~70bp from its 4Q level, led by increased SG&A expenses
- We expect growth to be driven by healthcare and BFS verticals
- The demand environment within its critical sectors and progress on stimulating growth levers would be closely monitored.

Quarterly performance

Y/E March		FY2	1		FY25E				FY24 FY25E			
	1Q	2Q	3Q	4Q	1QE	2QE	3QE	4QE				
Revenue (USD m)	149	150	145	148	151	157	161	167	592	636		
QoQ (%)	1.2	0.6	-3.7	2.3	2.3	3.5	2.6	3.5	-2.0	7.4		
Revenue (INR m)	12,272	12,408	12,041	12,297	12,636	13,084	13,427	13,902	49,018	53,050		
YoY (%)	2.0	0.5	0.5	1.4	3.0	5.5	11.5	13.1	1.1	8.2		
GPM (%)	33.6	31.8	31.1	30.6	33.5	33.0	33.0	33.0	31.8	33.1		
SGA (%)	14.9	13.2	13.9	14.1	17.1	16.6	16.8	16.9	14.0	16.8		
EBITDA	2,301	2,308	2,076	2,030	2,072	2,146	2,175	2,238	8,715	8,632		
EBITDA margin (%)	18.8	18.6	17.2	16.5	16.4	16.4	16.2	16.1	17.8	16.3		
EBIT	1,878	1,942	1,764	1,793	1,756	1,819	1,839	1,891	7,377	7,305		
EBIT margin (%)	15.3	15.7	14.6	14.6	13.9	13.9	13.7	13.6	15.0	13.8		
Other income	224	306	356	493	164	170	175	181	1,379	690		
ETR (%)	25.7	22.7	23.8	24.2	24.3	24.3	24.3	24.3	24.1	24.3		
Adj. PAT	1,562	1,738	1,616	1,733	1,454	1,506	1,525	1,569	6,649	6,054		
QoQ (%)	30.9	11.3	-7.0	7.2	-16.1	3.5	1.3	2.9				
YoY (%)	108.0	206.0	111.2	45.3	-6.9	-13.3	-5.6	-9.5	102.9	-8.9		
EPS (INR)	6.8	7.6	7.1	7.6	6.4	6.6	6.7	6.9	29.1	26.5		

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

NOTES

Explanation of Investment Rating							
Investment Rating	Expected return (over 12-month)						
BUY	>=15%						
SELL	<-10%						
NEUTRAL	< - 10 % to 15%						
UNDER REVIEW	Rating may undergo a change						
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation						

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend. Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at http://onlinere

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage pending Motilal Proceedings Oswal Limited transactions. Details of Enquiry Financial Services available of are on https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In relates on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

- MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- 2 MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company
- MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- Research Analyst has not served as director/officer/employee in the subject company
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- MOFSL has not received compensation for investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- MOFSL has not received any compensation or other benefits from third party in connection with the research report
- MOFSL has not engaged in market making activity for the subject company

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months

- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No::022-40548085.

Grievance Redressal Cell:

Chiefranio Trodi cocci Coli.								
Contact Person	Contact No.	Email ID						
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com						
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com						
Mr. Ajay Menon	022 40548083	am@motilaloswal.com						

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN .: 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.